Back to dashboard
All PlansCoverageMedium impact

Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Metastatic Colorectal Cancer (KRAS, NRAS, BRAF, and HER2)

Blue Cross & Blue Shield of Mississippi·MS · Oncology, Hematology, Gastroenterology +1 more·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply
—

Summary

This is a new medical policy establishing coverage criteria for somatic biomarker testing (including liquid biopsy) for targeted treatment in metastatic colorectal cancer, specifically for KRAS, NRAS, BRAF, and HER2 testing. The policy provides detailed coverage guidelines for both tissue-based and circulating tumor DNA testing to guide targeted therapy decisions.

Action Required

Action needed
Immediately: Review the complete policy document to understand coverage criteria for biomarker testing in metastatic colorectal cancer patients. Billing team should verify that orders for KRAS, NRAS, BRAF, and HER2 testing (including liquid biopsy) meet the established medical policy criteria before submission. Ensure proper documentation supports medical necessity for targeted therapy selection.

Related policy hubs